Overactive Bladder
📧 Sign up to get email alerts when something new happens for Overactive Bladder.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2012-02-10Clinical Trial Update: Efficacy and Tolerability of Propiverine Hydrochloride in Patients With Neurogenic Detrusor Overactivity [Phase 3]
Phase 3 trial evaluating propiverine hydrochloride for neurogenic detrusor overactivity has completed.
-
CLINICAL_TRIALS trial_result · 2012-02-02Clinical Trial Update: MILADY: A Randomized, Placebo-controlled Safety and Efficacy Trial of SSR240600C in Treatment of Overactive Bladder or Urge Urinary Incontinence. [Phase 2]
A Phase 2 randomized, placebo-controlled trial evaluating the safety and efficacy of SSR240600C in adults with overactive bladder has comple…
-
CLINICAL_TRIALS trial_result · 2012-01-25Clinical Trial Update: Propiverine Hydrochloride Extended-Release Capsule for Overactive Bladder [Phase 3]
Phase 3 trial update for Propiverine Hydrochloride Extended-Release Capsule in Overactive Bladder; the study has completed.
-
CLINICAL_TRIALS trial_result · 2012-01-19Clinical Trial Update: Bryophyllum Versus Placebo for Overactive Bladder [Phase 2]
The Phase 2 trial evaluating Bryophyllum versus placebo for overactive bladder has completed.
-
FDA label_change · 2012-01-17FDA Approved: VESICARE — Supplemental Application (Astellas Pharma US, Inc.)
The FDA approved a supplemental application for Vesicare (solifenacin succinate) submitted by Astellas Pharma US, Inc. to amend the product'…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2012-01-09Clinical Trial Update: This Is A Study Of Bioavailability And Food Effect For Fesoterodine. [Phase 1]
Pfizer conducted a Phase 1 study to assess the bioavailability of fesoterodine and the effect of food on its pharmacokinetics in adults with…
-
FDA approval · 2011-12-30FDA Approved: TOVIAZ — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
The FDA approved a supplemental application for TOVIAZ (fesoterodine fumarate) submitted by Pfizer Laboratories Div Pfizer Inc.
-
CLINICAL_TRIALS trial_result · 2011-12-19Clinical Trial Update: Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART) Trial [Phase 4]
The SMART Phase 4 trial of Sanctura (trospium chloride) assessing pharmacokinetics in elderly participants has completed, with results poste…
-
CLINICAL_TRIALS trial_result · 2011-12-14Clinical Trial Update: A Study to Compare the Effectiveness and Safety of Fesoterodine and Placebo in an Elderly Population of Patients Who go to the Toilet Very Frequently Due to Overactive Bladder. [Phase 4]
Phase 4 clinical trial comparing fesoterodine to placebo in elderly patients with overactive bladder; the study assessed effectiveness and s…
-
CLINICAL_TRIALS trial_result · 2011-11-30Clinical Trial Update: Transdermal (TDS) Oxybutynin (Oxytrol(r)) in Overactive Bladder [Phase 4]
Phase 4 clinical trial of transdermal oxybutynin (Oxytrol) for overactive bladder has been completed.
-
CLINICAL_TRIALS trial_result · 2011-11-24Clinical Trial Update: Bringing Simple Urge Incontinence Diagnosis & Treatment to Providers (BRIDGES) [Phase 4]
Phase 4 BRIDGES trial evaluated strategies for diagnosing and treating simple urge urinary incontinence among providers. Results were posted…
-
CLINICAL_TRIALS trial_result · 2011-11-17Clinical Trial Update: Study Of Fesoterodine In Pediatric Overactive Bladder Patients Aged 8-17 Years [Phase 2]
Phase 2 clinical trial of fesoterodine in pediatric patients (ages 8-17) with overactive bladder or neurogenic detrusor overactivity has bee…
-
CLINICAL_TRIALS trial_result · 2011-11-17Clinical Trial Update: A Study of Solifenacin Succinate Compared to Tolterodine in Patients With Overactive Bladder [Phase 3]
Phase 3 clinical trial comparing solifenacin succinate with tolterodine for overactive bladder has completed.
-
FDA approval · 2011-11-04FDA Approved: OXYBUTYNIN CHLORIDE — Supplemental Application (Strides Pharma Science Limited)
FDA approved a supplemental application for oxybutynin chloride from Strides Pharma Science Limited, expanding access to this generic treatm…
-
FDA approval · 2011-11-02FDA Approved: OXYBUTYNIN CHLORIDE — Supplemental Application (Lannett Company, Inc.)
FDA approved a supplemental application for oxybutynin chloride from Lannett Company, expanding the availability of a generic formulation.
-
FDA approval · 2011-11-01FDA Approved: TOVIAZ — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
The FDA approved a supplemental application for TOVIAZ (fesoterodine fumarate) submitted by Pfizer Laboratories Div Pfizer Inc. This action …
-
FDA approval · 2011-10-28FDA Approved: OXYBUTYNIN CHLORIDE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for oxybutynin chloride from Teva Pharmaceuticals USA, Inc.
-
CLINICAL_TRIALS trial_result · 2011-10-28Clinical Trial Update: Hypnotherapy for Treatment of Overactive Bladder [NA]
A completed clinical trial evaluating hypnotherapy as a treatment for overactive bladder; results were posted in 2011.
-
CLINICAL_TRIALS trial_result · 2011-10-17Clinical Trial Update: Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder [Phase 3]
A Phase 3 safety and efficacy study of botulinum toxin type A for neurogenic overactive bladder has completed, with results posted in 2011.
-
CLINICAL_TRIALS trial_result · 2011-10-17Clinical Trial Update: Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder [Phase 3]
A Phase 3 clinical trial evaluated the safety and efficacy of Botulinum toxin Type A for neurogenic overactive bladder; results were posted …
-
CLINICAL_TRIALS trial_result · 2011-10-17Clinical Trial Update: Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder [Phase 2]
A Phase 2 study evaluating botulinum toxin type A for neurogenic overactive bladder was terminated; results were posted in 2011.
-
CLINICAL_TRIALS trial_result · 2011-10-12Clinical Trial Update: Evaluation of Adherence to Solifenacin Treatment in Overactive Bladder Patients
Astellas-sponsored trial assessed adherence to solifenacin therapy in patients with overactive bladder. The study status is completed.
-
FDA approval · 2011-09-20FDA Approved: DETROL LA — Supplemental Application (Viatris Specialty LLC)
FDA approved a supplemental application for DETROL LA (tolterodine tartrate) from Viatris Specialty LLC.
-
FDA approval · 2011-09-20FDA Approved: TOLTERODINE TARTRATE — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for tolterodine tartrate filed by Mylan Pharmaceuticals Inc.
-
CLINICAL_TRIALS research · 2011-08-26Clinical Trial Update: Comparison of Solifenacin and Oxybutynin in the Treatment of Overactive Bladder [Phase 4]
Phase 4 clinical trial update comparing solifenacin to oxybutynin for overactive bladder; no trial results are provided in the snippet.